AbbVie

ABBV

Market cap $400B

Dividend growth is a reliable edge. Over long periods, companies that regularly raise their dividends have often outperformed the benchmark S&P 500 (^GSPC 0.72%), as sustained payout increases typically stem from stronger, growing earnings.

ABBV leans on booming Skyrizi and Rinvoq-driven sales to sustain growth and counter Humira's decline as Q3 results approach.

The Investment Committee give you their top stocks to watch for the second half.

-        Updated indication allows the use of RINVOQ® (upadacitinib) prior to the use of tumor necrosis factor (TNF) blocking agents in patients for whom use of these treatments is clinically inadvisable and who have received at least one approved systemic therapy NORTH CHICAGO, Ill. , Oct. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) approval of a supplemental new drug application (sNDA) that updates the indication statement for RINVOQ® (upadacitinib) for the treatment of adults with moderately to severely active ulcerative colitis (UC) and moderately to severely active Crohn's disease (CD).

Dividend stocks never go out of style, but they might be even more worthy of consideration right now because some evidence suggests that troubles lie ahead. The government shutdown and remaining uncertainty regarding tariffs could rock the economy or equity markets (or both).

New data from telisotuzumab adizutecan (Temab-A) and ABBV-706 across pancreatic, colorectal, and solid tumors, highlight progress in AbbVie's growing ADC portfolio designed to target difficult-to-treat cancers. NORTH CHICAGO, Ill.

Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Carolina Wealth Advisors, LLC disclosed in an Oct. 7, 2025, U.S. Securities and Exchange Commission filing that it sold 38,267 AbbVie shares for the quarter ended Sept. 30, 2025, an estimated $7.79 million trade based on quarterly average pricing.

Lilly's explosive GLP-1 growth and AbbVie's post-Humira rebound set up a fierce 2025 showdown between two pharma powerhouses.

By the makers of BOTOX® Cosmetic (onabotulinumtoxinA), SkinMedica®'s new packaging features a refreshed logo, modernized look, and luxe copper color palette. The brand's new HA5® moisturizer is designed to support the skin barrier and microbiome for bouncy, dewy, and soft skin.